HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) MARKET ANALYSIS

High Intensity Focused Ultrasound (HIFU) Market, By Imaging Technology (Ultrasound- HIFU Therapy, and Magnetic Resonance Imaging- HIFU Therapy), By Indication (Oncology {Prostate cancer, Rectal tumors, Liver tumors, Renal tumors, others}, Skin Care {Anti-aging treatment, Skin Laxity and Tightening, Others}, Neurological Disorders, and Others), By End User (Hospitals, Ambulatory Surgical Centers, Dermatology Clinics, and Others), And by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Feb 2023
Code : CMI5538
Pages :182
Formats :
Excel and PDF
Industry : Medical Devices

Market News

Global High-Intensity Focused Ultrasound (HIFU) Market: Key Developments

In November 2022, Nomura Holdings, Inc., a Japan- based financial holding company, acquired shares of SONIRE Therapeutics Inc., a company developing a next-generation high-intensity focused ultrasound (HIFU) treatment system. The investment made by the Nomura Holdings, Inc. will benefit the SONIRE Therapeutics Inc. to develop a HIFU treatment system for the treatment of pancreatic cancer as well as other types of cancers.

In November 2021, Zealand University Hospital started a research on HIFU for the treatment of Basal Cell Carcinoma (BCC). The investigation entails assessing the safety and efficacy profile of three months after a single 3-5 minute treatment. Secondary endpoints are followed up on every third month, until the study concludes one year after treatment. The study is expected to complete by December 2024.

In November 2020, EDAP TMS, a medical device company that develops, manufactures, and markets minimally invasive medical devices using ultrasound technology for various medical applications, announced a distribution agreement with AB Medica, an Italy-based company specialized in creation and distribution of medical technologies. The agreement between two companies will extend the availability of EDAP TMS’s High-Intensity Focused Ultrasound (HIFU) technology across Italy.

Hospices Civils de Lyon, France's second university hospital center (CHU) initiated a study evaluating the efficacy and tolerability of focused HIFU (High Intensity Focused Ultrasound) therapy compared to active surveillance in patients with significant low risk prostate cancer. The study is in phase 3 of clinical trials and is expected to be complete in October 2026.